Health Care • Biotechnology: Pharmaceutical Preparations
$1.25 ▼ -0.09
(-6.72%)
MKT CAP: $2.4M • VOL: 15.5K
52W L $1 52W H $10
SILO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $72.1K | $72.1K | $72.1K |
| YoY Revenue Growth % | 0.0% | 0.0% | — |
| Gross Profit | $27.8K | $66.3K | — |
| Gross Margin % | 38.6% | 91.9% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$4.3M | -$4.7M | -$3.9M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$4.2M | -$4.4M | -$3.7M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$4.7M | -$3.8M | -$3.2M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$4.7M | -$3.8M | -$3.2M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $4.7M | $3.9M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $6.3M | $5.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SILO.